Re­gen­eron, Sanofi rack up a PhI­II asth­ma win for dupilum­ab; Ve­rastem preps FDA app for du­velis­ib

Re­gen­eron and Sanofi say their tri­al of Dupix­ent (dupilum­ab) hit the pri­ma­ry and key sec­ondary end­points in a Phase III asth­ma study. Their drug re­duced the use of steroids by 70%, com­pared to 42% for the place­bo arm. “Im­por­tant­ly, de­spite a re­duc­tion in oral cor­ti­cos­teroid use, dupilum­ab was as­so­ci­at­ed with an im­prove­ment in lung func­tion. This is the third study in which dupilum­ab has demon­strat­ed a re­duc­tion in asth­ma at­tacks and im­prove­ment in lung func­tion in a broad group of pa­tients with un­con­trolled asth­ma – this ef­fect was most pro­found in pa­tients with el­e­vat­ed mark­ers of Type 2 al­ler­gic in­flam­ma­tion, such as an eosinophil count over 300,” said Re­gen­eron chief sci­en­tist George Yan­copou­los.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.